Axsome Therapeutics (AXSM) Current Assets (2015 - 2026)

Axsome Therapeutics has disclosed Current Assets across 12 years of filings, most recently posting $611.2 million for Q1 2026.

• Current Assets for Q1 2026 came in at $611.2 million, up 23.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $611.2 million (up 23.57% YoY), and the FY2025 annual result was $589.0 million, up 21.42% from the prior year.
• Current Assets came in at $611.2 million for Q1 2026 at Axsome Therapeutics, up from $589.0 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $611.2 million in Q1 2026 to a low of $86.8 million in Q1 2022.
• The 5-year median for Current Assets is $485.1 million (2024), against an average of $424.3 million.
• Across the five-year window, Current Assets sank 47.39% in 2022 and surged 399.81% in 2023, its largest moves.
• Axsome Therapeutics' Current Assets stood at $245.6 million in 2022, then soared by 105.28% to $504.3 million in 2023, then declined by 3.81% to $485.1 million in 2024, then increased by 21.42% to $589.0 million in 2025, then climbed by 3.77% to $611.2 million in 2026.
• The last three Current Assets figures came in at $611.2 million (Q1 2026), $589.0 million (Q4 2025), and $565.3 million (Q3 2025), per Business Quant data.